SKU LUM-SEMA-5 · C₁₈₇H₂₉₁N₄₅O₅₉ · 4113.58 g/mol · CAS 910463-68-2
A 31-residue GLP-1 receptor agonist with a fatty-acid side chain at Lys26 for albumin-mediated half-life extension. Lyophilized from acetate buffer; reconstitute with bacteriostatic water for in-vitro receptor assays.
Purity (HPLC)
≥ 99.41%
Net peptide
5.00 mg ± 2%
Endotoxin
< 0.5 EU/mg
Format
Lyophilized vial
Storage
−20 °C, desiccated
Shelf life
24 months from MFG
$85CAD/ 10 mg vial
In stock · Lot LM-2602
Qty
Add $300 for Free shipping
HPLC + MS verified per lot
~4 days to your door
COA bundled with shipment
Lot samples retained 5 years
Overview
Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist used as a reference standard in metabolic and incretin-axis research. The C18 fatty diacid attached at Lys26 binds serum albumin reversibly, conferring a 165-hour effective half-life in mammalian models and reducing assay-to-assay drift in time-course studies.
Each vial is lyophilized from acetate-buffered solution at pH 4.0, sealed under nitrogen, and held through ship. Insulated tracked shipping is maintained from our lab to your bench.
Research applications
In-vitro GLP-1R potency assays, β-arrestin recruitment screens, comparative pharmacokinetics versus exenatide and liraglutide, and structural studies of receptor-bound conformations. Compatible with HEK293, CHO, and INS-1E cell lines.
Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.
Identity
Parameter
Value
Molecular formula
C₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight
4113.58 g/mol
CAS number
910463-68-2
Sequence length
31 residues
Modification
γ-Glu-C18 diacid at Lys26
Quality
Test
Specification
HPLC purity
99.383%
Mass confirmation
ESI-MS within 0.5 Da
Net peptide content
≥ 80% by AAA
Endotoxin
< 0.5 EU/mg (LAL)
Bioburden
< 10 CFU/g
Residual TFA
< 1.0%
Lot LM-2602
Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Canada. Retain samples held under storage spec for five years from release date.
Verification
Method
Result
RP-HPLC at 220 nm
99.41% main peak
ESI-MS (positive)
4113.6 Da (theor. 4113.58)
Amino acid analysis
82.1% net peptide
LAL endotoxin
< 0.05 EU/mg
Karl Fischer (water)
2.8% w/w
Reconstitution
Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.
Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.
Storage after reconstitution
Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.
Selected references
Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155.
Lau J et al. Discovery of the once-weekly GLP-1 analogue semaglutide. J Med Chem. 2015;58(18):7370–80.
Semaglutide is a long-acting GLP-1 analog, classified within the incretin signaling pathway. Structurally it is a C20 fatty-diacid GLP-1R agonist. Semaglutide is a 31-residue analog of human glucagon-like peptide-1 (GLP-1) bearing a C18 diacid attachment via a γ-glutamyl spacer at Lys26. Lau et al. (2015) reported its discovery and characterized its sub-nanomolar GLP-1R potency and extended functional half-life. Marso et al. (2016) followed with the SUSTAIN-6 cardiovascular outcomes data.
In an in-vitro setting, Semaglutide interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable until reconstituted.
Common research applications
In-vitro receptor-binding and dose-response screens against the incretin signaling target panel.
Comparative pharmacology against related class members and previously published reference standards.
Time-course studies leveraging Semaglutide's known stability profile.
Cross-batch HPLC fingerprint comparison against the lot-specific COA we publish for every release.
Storage & handling
Semaglutide arrives lyophilized in Canada Post (~4 days). On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.
References
Lau J et al. J Med Chem. 2015;58(18):7370-80.
Marso SP et al. N Engl J Med. 2016;375(19):1834-44.
Knudsen LB. Front Endocrinol. 2019;10:155.
For laboratory research only. Semaglutide is sold strictly as an in-vitro reference standard. Sold as an in-vitro reference standard, not as a Health Canada or FDA-approved therapeutic.